ADE (chemotherapy)
Medical intervention
From Wikipedia, the free encyclopedia
ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.
| ADE | |
|---|---|
| Specialty | Oncology |
ADE regimen consists of three drugs:
- Ara-C (cytarabine) - an antimetabolite;
- Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
- Etoposide - a topoisomerase inhibitor.[1]
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| Ara-C (cytarabine) | 200 mg/m2 | IV push every 12 hours in 2 divided doses (100 mg/m2 each) | Days 1-10 |
| Daunorubicin | 50 mg/m2 | IV slow push | Days 1, 3 and 5 |
| Etoposide | 100 mg/m2 | IV infusion over 1 hour | Days 1-5 |